According to the terms of the agreement, Yoshindo will have exclusive marketing rights in Japan for Biocon Biologics' bUstekinumab and bDenosumab, for a USD 700 million# addressable market potential. Biocon Biologics will be paid an upfront licensing fee as well as future payments if specific development milestones are met over the following few years. The financial specifics of the arrangement are kept private.
Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody that is used to treat psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Denosumab, a biosimilar to Prolia, is a monoclonal antibody used to treat osteoporosis.
Biocon Biologics' strategic agreement with Yoshindo will build on the company's significant accomplishments in its worldwide development programmes for these two biosimilar products. Clinical trials for these two assets began in FY22, and they include both Phase 1 and Phase 3 trials, as well as sophisticated pre-clinical CMC packages.
Biocon Biologics is creating a comprehensive portfolio of 20 biosimilar assets, either individually or through strategic alliances, to supply patients with affordable biologics and allow health equity.
At around 9.18 AM, Biocon was trading at Rs261.45 up by 0.06% from its previous closing of Rs261.30 on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.